About us
The independent Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) examines the benefits and harms of medical interventions for patients.
Projects
Participation
Events
Press
Contact
Breadcrumbs
Last updated 08.01.2024
Project no.: A22-34
Commission: Commission awarded on 18.03.2022 by the Federal Joint Committee (G-BA).
Report type: Report
Status: Commission completed
Department/Division: Drug Assessment
Application field: Mental and emotional wellbeing
https://dx.doi.org/10.60584/A22-34
Final report: Benefit assessment of bupropion, cytisine, nicotine and varenicline for tobacco cessation in severe tobacco dependence
published on Jan 8, 2024
Documentation of comments on the preliminary report: Benefit assessment of bupropion, cytisine, nicotine and varenicline for tobacco cessation in severe tobacco dependence
Preliminary report: Benefit assessment of bupropion, cytisine, nicotine and varenicline for tobacco cessation in severe tobacco dependence
published on Sep 12, 2023
Documentation of comments on the report plan: Benefit assessment of bupropion, cytisine, nicotine and varenicline for tobacco cessation in severe tobacco dependence
Report plan: Benefit assessment of bupropion, cytisine, nicotine and varenicline for tobacco cessation in severe tobacco dependence
published on Aug 31, 2022
Press contact
+49 221 356850
presse@iqwig.de
Info Service (German)
Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.
Contact form
Questions about commissions, publications and press releases can be sent to us via this form.
